Anle138b treats Huntington's disease

Researchers from the University of Würzburg, led by Irina Dudanova and Miguel da Silva Padilha, have published a study in EMBO Molecular Medicine detailing the efficacy of an experimental drug, anle138b, in treating Huntington's disease. The drug, developed by teams including Christian Griesinger from the Max Planck Institute of Multidisciplinary Sciences and Armin Giese from LMU Munich (now at MODAG GmbH), has shown promising results in alleviating symptoms, extending lifespan in mouse models, and reducing toxic protein clumps in human stem cells. This compound targets the underlying cause of the disease by preventing harmful protein aggregates from destroying nerve cells, offering a potential breakthrough for this previously incurable hereditary disorder. The findings also suggest anle138b's potential for other neurodegenerative diseases, with a clinical trial already underway for multiple system atrophy.